
GoHealth, Inc. (GOCO) Stock Forecast & Price Target
GoHealth, Inc. (GOCO) Analyst Ratings
Bulls say
GoHealth Inc. reported a significant year-over-year revenue growth of 19.1% in Q1 2025, achieving $221.0 million, which surpassed both internal estimates and consensus forecasts. The company experienced a robust increase in total submissions, growing by 40.2% year-over-year to 303,000, primarily driven by a notable 64% growth in captive Medicare submissions, while agent headcount only increased by 24%. Additionally, membership persistency and lifetime value (LTV) have stabilized over the past two years, indicating a positive trend in the company's customer retention and overall market strategy amidst industry adjustments.
Bears say
GoHealth Inc. is experiencing a decline in revenue per sale, which fell by 15.4% to $724, primarily attributed to a shift in submission types from non-agency to agency. Despite a substantial year-over-year improvement in adjusted EBITDA, with a reported figure of $42.1 million in Q1 2025, the company faces potential headwinds in persistency that could negatively impact future revenue and cash received from commissions. The downside scenario analysis indicates a possibility of adjusted EBITDA being approximately 25% lower than base case estimates, suggesting a decreased valuation multiple of the company's earnings.
This aggregate rating is based on analysts' research of GoHealth, Inc. and is not a guaranteed prediction by Public.com or investment advice.
GoHealth, Inc. (GOCO) Analyst Forecast & Price Prediction
Start investing in GoHealth, Inc. (GOCO)
Order type
Buy in
Order amount
Est. shares
0 shares